Company news

Ovid Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

September 25, 2023

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 19, 2023

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

August 29, 2023

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

August 3, 2023

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

July 31, 2023

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

June 27, 2023

Ovid Therapeutics Added to Russell 3000® Index

June 25, 2023

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

May 4, 2023

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

April 30, 2023

Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 9, 2023

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

March 12, 2023

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

March 8, 2023

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

March 7, 2023

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

February 27, 2023

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

February 7, 2023

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

January 4, 2023

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

December 1, 2022

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

November 7, 2022

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

September 26, 2022

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

August 8, 2022

Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

June 5, 2022

Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

May 9, 2022

Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

April 7, 2022

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results

March 14, 2022

Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

March 3, 2022

Healx and Ovid Therapeutics to Enter Strategic Partnership

February 7, 2022

Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

January 2, 2022

Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results

November 9, 2021

Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors

October 6, 2021

Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

August 15, 2021

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

July 7, 2021

Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

July 6, 2021

Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer

June 3, 2021

Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board

May 25, 2021

Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 12, 2021

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

May 11, 2021

Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board

April 19, 2021

OVID Provides Update on OV101 Program and the Prioritization of its Resources

April 18, 2021

Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat

March 29, 2021

Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021

March 14, 2021

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

March 2, 2021

Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index

December 15, 2020

Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint

November 30, 2020

Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress

November 22, 2020

Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 11, 2020

Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program

October 13, 2020

Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress

October 11, 2020

Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies

September 29, 2020

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 28 decks. Every deck is listed under its year.